Literature DB >> 11092260

De novo acute hepatitis B infection in a previously vaccinated liver transplant recipient due to a strain of HBV with a Met 133 Thr mutation in the "a" determinant.

E M Yoshida1, A Ramji, S R Erb, J E Davis, U P Steinbrecher, C H Sherlock, C H Scudamore, S W Chung, M Williams, K S Gutfreund.   

Abstract

UNLABELLED: De novo HBV infection post-liver transplantation (LT) from an anti-HBc seropositive donor rarely presents as acute failure. We report a 42-year-old Caucasian female, HBsAg and anti-HBc seronegative, with primary biliary cirrhosis who received an allograft from a HBsAg negative, anti-HBc seropositive donor. The patient, previously vaccinated years pre-LT, was re-vaccinated against HBV and 1 year post-LT had an anti-HBs titre of 256 IU/l. Two years post-LT, elevated serum aminotransferases and worsening liver function with an INR of 2.0 developed. The HBsAg became positive, anti-HBs undetectable and serum HBV-DNA >2000 pg/ml by hybridisation assay. Liver biopsy revealed significant ballooning degeneration, piecemeal necrosis and positive immunostaining for HBsAg. Progressive liver failure developed followed by sepsis and terminal multi-organ failure. Subsequent analysis of the predominant HBV strain revealed mutations in the "a" determinant: Met 133 Thr (codon change ATG to ACG) and Asn 131 Thr.
CONCLUSION: ' Acute de novo HBV infection from an anti-HBc sero-positive donor may occur long after LT despite protective anti-HBs titres post-vaccination secondary to the emergence of "a" determinant mutated strains of HBV.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11092260     DOI: 10.1034/j.1600-0676.2000.020005411.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  7 in total

1.  HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patients.

Authors:  Timothy Na Archampong; Ceejay L Boyce; Margaret Lartey; Kwamena W Sagoe; Adjoa Obo-Akwa; Ernest Kenu; Jason T Blackard; Awewura Kwara
Journal:  Antivir Ther       Date:  2016-05-11

2.  Current use of hepatitis B immune globulin for prevention of de novo hepatitis B in recipients receiving anti-HBc-positive livers.

Authors:  Jen-Jung Pan; Nirav Thosani; Victor I Machicao; Michael B Fallon
Journal:  Hepatol Int       Date:  2011-01-22       Impact factor: 6.047

3.  A YIDD Mutation in a Case of Recurrent Hepatitis B after Liver Transplantation Induced by an S-escape Mutant.

Authors:  Yun-Jung Oh; Young-Min Park; Sun-Pyo Hong; Soo-Kyeong Shin; Seung-Il Ji; Bo-Hyun Kim; Sang-Jong Park; Zheng Hong
Journal:  Gut Liver       Date:  2010-06-16       Impact factor: 4.519

4.  Functional analysis of 'a' determinant mutations associated with occult HBV in HIV-positive South Africans.

Authors:  Eleanor A Powell; Ceejay L Boyce; Maemu P Gededzha; Selokela G Selabe; M Jeffrey Mphahlele; Jason T Blackard
Journal:  J Gen Virol       Date:  2016-03-31       Impact factor: 3.891

5.  Hepatitis B virus S gene escape mutants.

Authors:  Michael A Purdy
Journal:  Asian J Transfus Sci       Date:  2007-07

6.  De Novo Superinfection of Hepatitis B Virus in an Anti-HBs Positive Patient with Recurrent Hepatitis C Following Liver Transplantation.

Authors:  Sung-Hae Ha; Young-Min Park; Sun-Pyo Hong; So-Ya Back; Soo-Kyeong Shin; Seung-Il Ji; Soo-Ok Kim; Wang-Don Yoo; Bo-Hyun Kim; Sang-Jong Park; Zheng Hong
Journal:  Gut Liver       Date:  2011-06-23       Impact factor: 4.519

7.  Seroprevalences of hepatitis B virus and hepatitis C virus among participants of an Asian health fair in the Lower Mainland, British Columbia.

Authors:  Stephen Ip; Jo-Ann Ford; Kirby Lau; Vladimir Marquez; Marisa Guan; Carolyn Klassen; Jessica Chan; Wc Peter Kwan; Mel Krajden; Eric M Yoshida
Journal:  Can J Infect Dis Med Microbiol       Date:  2015 Jul-Aug       Impact factor: 2.471

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.